Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 153 The United Laboratories International Holdings Limited Annual Report 2025 42. INFORMATION ABOUT THE STATEMENT OF FINANCIAL POSITION OF THE COMPANY (Continued) (b) Reserves Share premium Shares held for share award scheme Share-based compensation reserve Retained profits Total RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 At 1 January 2024 3,722,482 – 6,365 1,061,148 4,789,995 Profit and total comprehensive income for the year – – – 139,492 139,492 Dividends recognised as distribution (Note 15) – – – (1,017,535) (1,017,535) Purchase of shares for share award scheme – (36,465) – – (36,465) Transaction cost attributable to purchase of shares for share award scheme – (112) – – (112) Vesting of shares – 35,539 (24,693) (10,846) – Recognition of share-based compensation expense – – 47,364 – 47,364 At 31 December 2024 3,722,482 (1,038) 29,036 172,259 3,922,739 Profit and total comprehensive income for the year – – – 1,263,147 1,263,147 Dividends recognised as distribution (Note 15) – – – (1,042,496) (1,042,496) Issue of shares 1,988,451 – – – 1,988,451 Purchase of shares for share award scheme – (41,423) – – (41,423) Transaction cost attributable to purchase of shares for share award scheme – (130) – – (130) Vesting of shares – 40,016 (23,074) (16,942) – Recognition of share-based compensation expense – – 14,093 – 14,093 At 31 December 2025 5,710,933 (2,575) 20,055 375,968 6,104,381